About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Localized Leiomyosarcoma Biomarker Protocol | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNCT04925089

Localized Leiomyosarcoma Biomarker Protocol

* Leiomyosarcoma (LMS) is one of the more common soft tissue sarcomas (STS). * Patients presenting with large, high-grade, localized LMS are at significant risk of developing metastasis following cura...

Lead sponsor: University of Michigan Rogel Cancer Center•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Scott Schuetze

CONTACT

7346478921 scotschu@med.umich.edu

Sponsors

Lead Sponsor

University of Michigan Rogel Cancer Center

Collaborators

National Cancer Institute (NCI)

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with localized leiomyosarcoma (LMS) of extremity, body wall or retroperitoneum
•Grade 2 or 3, or high-grade LMS
•Tumor size \>5 cm in greatest dimension
•Primary tumor amenable to complete resection
•There is no age requirement
•Participant agrees to receive neoadjuvant doxorubicin and ifosfamide combination chemotherapy
•If pre-operative radiation is administered, it must be administered after chemotherapy. Post-operative radiation may be administered
•Archival tumor tissue (either frozen sample, tissue block containing tumor, or minimum of 4 unstained slides and 1 H\&E stained slide) from diagnostic or pre-treatment biopsy available for study research

Related studies

RECRUITINGPhase 2

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

NCT07467772 · Uterine Sarcoma, Uterine Leiomyosarcoma, and more

RECRUITINGPhase 3

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290 · Leiomyosarcoma

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

NCT07432932 · Sarcoma, Sarcoma, Leiomyo-, Adult, and more

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

NCT04055220 · Bone Sarcoma, Osteosarcoma, and more

RECRUITINGPhase 2

XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

NCT06571734 · Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 17, 2026Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment40

Start dateApr 2023

Last updatedFeb 17, 2026

Condition

Locations shown

University of Michigan

Ann Arbor, Michigan

Mayo Clinic

Rochester, Minnesota

Vanderbilt University Medical Center

Nashville, Tennessee

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions